Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Equity Ratio (2016 - 2025)

Ironwood Pharmaceuticals' Equity Ratio history spans 16 years, with the latest figure at 0.66 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 23.18% year-over-year to 0.66; the TTM value through Dec 2025 reached 0.66, up 23.18%, while the annual FY2025 figure was 0.66, 23.18% up from the prior year.
  • Equity Ratio for Q4 2025 was 0.66 at Ironwood Pharmaceuticals, up from 0.67 in the prior quarter.
  • Across five years, Equity Ratio topped out at 2.88 in Q4 2023 and bottomed at 1.02 in Q1 2025.
  • The 5-year median for Equity Ratio is 0.2 (2021), against an average of 0.01.
  • The largest annual shift saw Equity Ratio surged 4380.41% in 2021 before it crashed 223.1% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.54 in 2021, then rose by 10.25% to 0.59 in 2022, then surged by 385.3% to 2.88 in 2023, then crashed by 129.85% to 0.86 in 2024, then increased by 23.18% to 0.66 in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Equity Ratio are 0.66 (Q4 2025), 0.67 (Q3 2025), and 0.9 (Q2 2025).